Regeneron Pharmaceuticals Inc (REGN)

[TREND1]

REGN one month closes

http://schrts.co/6vLghh

[TREND1]

Regeneron (REGN), a large-cap biotech stock, is part of the Health Care SPDR (XLV) and a top ten holding in the Biotech iShares (IBB), Both ETFs hit 52-week highs recently and show upside leadership. The stock is lagging in the 52-week high category, but the long-term trend is up and the stock is breaking out of a flag formation.
First, the long-term trend is up because the stock broke the March highs with a 39% advance from May to August. Second, the 50-day EMA is above the 200-day EMA and price is above both EMAs.
After breaking the red resistance zone in early July, the stock established support in the 360 area over the last few months. Even after a gap down in early August, the stock held this support zone and moved above the early August high. The stock has since corrected with a falling flag of sorts and is edging above the trend line as I write (Monday morning, September 24th).


http://schrts.co/HscMEf


The indicator windows show upside volume increasing over the last few months and the PPO turning up. Note the advance began in mid May with a surge in upside volume and upside volume has largely outpaced downside volume the last four months. The PPO (5,30,5) flattened out just above the zero line and remains just below its signal line. A bullish signal line crossover would confirm the upturn on the price chart.

[T695]

I’m in for earnings next week

[T695]

Watching for reversal to start

[Inoviorulez]

https://seekingalpha.com/article/4124174-novartis-looks-challenge-regenerons-turf-will-win-war

[ValueInvestor15]

Fundamentals imply Regeneron $REGN is 9% undervalued w/ earnings expected Tuesday:

Fair Value Analysis

[Liam859]

$364 ready for another pop

[trendmkr]

Regeneron Faces Trouble With Eylea Amid Strong Sales http://marketexclusive.com/regeneron-pharmaceuticals-inc-nasdaqregn-faces-trouble-eylea-amid-strong-sales/36359/?icd1

[trendmkr]

Regeneron,Teva Hit Setback In Pain Study http://marketexclusive.com/regeneron-pharmaceuticals-inc-nasdaqregn-teva-pharmaceutical-industries-ltd-nyseteva-hit-setback-pain-study/34351/?icd1

[crudeoil24]

After Recent Disappointments, Ocular Thera Pleases -- Market Talk
45 minutes ago - DJNF
7:49 ET - Ocular Therapeutix (OCUL) ended yesterday's trading with a $157M market cap. Regeneron (REGN) has entered a deal with the biopharma to potentially pay OCUL nearly twice that in milestone payments as part of a retinal-disease collaboration. Bigger drugmakers have made dozens of such deals with developers in recent years as to not depend just on their own pipeline but potential novel treatments created by others. In a number of cases, such agreements have ended up being the first step to a buyout. OCUL is up 23% premarket at $7.77 after having slid 8.2% this month and trading at just half of early-June levels. Then, it released more disappointing clinical data. ([e-mail]; @kevinkingsbury)

[MinnieM]

$REGN - Regeneron: The Amazon Of Biotech?
http://seekingalpha.com/article/4009740-regeneron-amazon-biotech

Interesting article.

[Liam859]

Cha-ching$$$$

[spartex]

$400 price in. Call options exploding in value.

[spartex]

Yes very good range to load (leap options too), and now that Barron's has put out a cover page article on Regeneron this weekend, the stock should continue on an upward path through $400 and back towards $500 by end of year/early next year....

[Liam859]

$363/share good range to load here

[venturecapp]

Regeneron Pharmaceuticals Boasts Success With Its Arthritis Pain Molecule Trial

http://marketexclusive.com/regeneron-pharmaceuticals-inc-nasdaqregn-meets-success-arthritis-pain-molecule-trial/6227/?icd1

[EndtheFed1776]

OCAT the next REGN

OCAT just raised cash today in a very creative non-dilutative financing. They are about to start an efficacy trial for dry age-related macular degeneration (AMD) and a pivotal trial for Stargardt's macular degeneration (SMD). The stock was up 12% today. OCAT only has 40 million shares outstanding, and a market cap of only $150 million. Once they confirm the efficacy they saw in the P1 trial, this stock is going to $300 plus. The market, as REGN investors know, for AMD is HUGE!

Time to take some profits off the table here and invest them in OCAT, in my humble opinion. I see OCAT as being the next REGN and then some.

[blue finch]

Bingo today
Breakout possible

[GuTA]

BIIB crushed the IBB and the sector.

AMZN pull back dragged down the rest

Frustrating day

[KingDMC]

With this turd market be lucky if it holds green. Everything is getting killed.

[TheDrew]

I think pop to 575 then I'm going to go short!

[Secret Stocks]

so will the stock get a pop or a drop????!!??!?!!!

[DewDiligence]

FDA’s Praluent label is more restrictive than EMA’s: #msg-115671253.

[TREND1]

TARRYTOWN, N.Y. and PARIS, July 24, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicine Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorization of Praluent® (alirocumab), recommending its approval for use in certain adult patients with hypercholesterolemia. Praluent is an investigational fully human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).

"We are very pleased to receive a positive opinion from the CHMP for Praluent, and look forward to bringing Praluent to those in greatest need across Europe," said Elias Zerhouni, M.D., President, Global R&D, Sanofi. "Despite statins and other lipid-lowering therapies, many patients are unable to reach their LDL cholesterol goals, and may benefit from new therapeutic options such as Praluent."

The CHMP recommended Praluent in both a 75 mg and 150 mg dose be approved for the treatment of adult patients with primary hypercholesterolemia (heterozygous familial hypercholesterolemia [HeFH] and non-familial) or mixed dyslipidemia as an adjunct to diet: a) in patients unable to reach their low density lipoprotein cholesterol (LDL-C) goals with a maximally-tolerated statin, Praluent would be used in combination with a statin, with or without other lipid-lowering therapies; and b) for patients who are statin intolerant, or for whom a statin is contraindicated, Praluent would be used alone or in combination with other lipid-lowering therapies. The effect of Praluent on cardiovascular morbidity and mortality has not been determined. The most common adverse reactions were injection site reactions, upper respiratory tract signs and symptoms, and pruritus.

The European Commission (EC) is expected to make a final decision on the Marketing Authorization Application for Praluent in the European Union in late September. The CHMP opinion was based on the benefit-risk profile of Praluent, following review of efficacy and safety data from more than 5,000 patients across 10 pivotal Phase 3 double-blind trials ranging from six months to two years. Clinical data from the ODYSSEY Phase 3 program show consistent, positive results in reducing LDL-C.

"In our clinical trial program, Praluent significantly reduced LDL cholesterol among patients with high unmet needs, including those with high or very high cardiovascular risk and those with an inherited form of high cholesterol called familial hypercholesterolemia," said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President, Regeneron Laboratories. "In these trials, patients received Praluent as a single subcutaneous injection once every two weeks using either a 75 mg or 150 mg dose, providing flexible dosing options that can be tailored to an individual's cholesterol lowering needs."

The U.S. Food and Drug Administration has set a target action date of July 24 for the Biologics License Application (BLA) of Praluent. The safety and efficacy of Praluent have not been fully evaluated by any other regulatory authority.

About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis. For additional information about the company, please visit www.regeneron.com.

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Regeneron Forward-Looking Statements
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned, including without limitation Praluent®(alirocumab); unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, including without limitation Praluent; the impact of the opinion adopted by the European Medicine Agency's Committee for Medicinal Products for Human Use discussed in the news release on the European Commission's decision regarding the Marketing Authorization Application for Praluent in the European Union, as well as the previously reported recommendation of the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (the "FDA") on the possible regulatory approval of Praluent by the FDA; ongoing regulatory obligations and oversight impacting Regeneron's marketed products, research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare LLC, to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2014 and its Form 10-Q for the quarter ended March 31, 2015. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

[KingDMC]

Might get a pop here

[TheDrew]

Approved!!!!!

[TREND1]

REGN 30 D W M

[KingDMC]

Halted pending news

[TREND1]

REGN W

[TREND1]

REGN PF

[TREND1]

REGN W M

[TREND1]

REGN 30 D

[TREND1]

REGN D

[bundyelvis]

I think I lost a few bucks on this one. Lol

[OGSPECULATOR]

Further confirmation!!!

[OGSPECULATOR]

Yikes!!!

[Liam859]

This is how money is made fellas!

[Liam859]

Lol

[bundyelvis]

What was I thinking? lol

[Liam859]

Still looks great to me. Awesome post!!!

[stocktrademan]

$REGN recent news/filings

bullish
triangle resistance breakout
macd crossup
in the top bollinger band area

## source: finance.yahoo.com

Mon, 18 May 2015 20:21:44 GMT ~ Healthcare Winners and Losers: May 18, 2015


read full: http://finance.yahoo.com/video/healthcare-winners-losers-may-6-202126519.html
*********************************************************

Mon, 18 May 2015 16:51:27 GMT ~ Sanofi and Regeneron Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference

[at noodls] - - Phase 3 Clinical Trial in Uncontrolled Persistent Asthma Underway - Paris and Tarrytown, NY - May 18, 2015-Sanofi and Regeneron Pharmaceuticals, Inc. today shared additional positive results from an ...

read full: http://www.noodls.com/view/815ABAFFD2360AAE5EB82D15F0A60C9682DE544F
*********************************************************

Mon, 18 May 2015 16:31:00 GMT ~ 12:31 pm Regeneron Pharms and Sanofi (SNY) announce positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate-to-severe asthma


read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#regn
*********************************************************

Mon, 18 May 2015 16:30:00 GMT ~ Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference

[PR Newswire] - TARRYTOWN, N.Y. and PARIS, May 18, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today shared positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate-to-severe asthma, who are uncontrolled despite treatment with inhaled corticosteroids and long-acting beta agonists (ICS/LABA). As previously reported, the study met its primary endpoint of improving lung function in asthma patients with high blood eosinophil counts (HEos, greater than or equal to 300 eosinophilic cells/microliter). Such high counts are thought to be a marker for patients more likely to have "atopic" or "allergic" asthma. New data presented on secondary endpoints at the American Thoracic Society 2015 International Conference included positive results in study patients with low blood eosinophil counts (LEos, less than 300 eosinophilic cells/microliter), who are thought to be less likely to suffer from "allergic" asthma and thus less likely to respond to TH2 targeted therapies.

read full: http://finance.yahoo.com/news/regeneron-sanofi-announce-positive-pivotal-163000724.html
*********************************************************

Mon, 18 May 2015 15:33:00 GMT ~ Regeneron: Why It's Heading to $550


read full: http://blogs.barrons.com/stockstowatchtoday/2015/05/18/regeneron-why-its-heading-to-550/?mod=yahoobarrons&ru=yahoo
*********************************************************

$REGN charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$REGN company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/REGN/company-info
Ticker: $REGN
OTC Market Place: Not Available
CIK code: 0000872589
Company name: Regeneron Pharmaceuticals, Inc.
Incorporated In: NY, USA

$REGN share structure

## source: otcmarkets.com

Market Value: $49,539,462,703 a/o May 15, 2015
Shares Outstanding: 101,305,623 a/o Apr 16, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

$REGN extra dd links

Company name: Regeneron Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/REGN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/REGN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=REGN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=REGN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=REGN+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/REGN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/news - http://finance.yahoo.com/q/h?s=REGN+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/REGN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/REGN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/REGN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/REGN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/REGN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/REGN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/REGN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=REGN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/REGN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Regeneron+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Regeneron+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Regeneron+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/REGN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/REGN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/REGN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/REGN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/REGN/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/REGN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/REGN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=REGN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=REGN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=REGN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=REGN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=REGN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=REGN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=REGN+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/REGN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=REGN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/REGN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=REGN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/REGN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/REGN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/REGN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/REGN/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/REGN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/REGN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/REGN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=REGN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=REGN



$REGN DD Notes ~ http://www.ddnotesmaker.com/REGN

[bundyelvis]

Had to short. I don't believe they will hit there numbers.

[bundyelvis]

Regn. Big day for Bio-Tec rebound.

[bundyelvis]

Time to buy. 446.00.

[OGSPECULATOR]

Alert confirmed$$$

[Liam859]

Love seein my account go up with REGN!!!! $$$$$

[DewDiligence]

NVS’ wet-AMD drug, RTH258 hits primary endpoint in phase-2 trial:

#msg-111253341

[jimmybob]

$REGN reports Q4 EPS $2.79, consensus $2.82
Reports Q4 revenue $802.33M, consensus $781.52M

[General Grievous]

fwiw...i just enrolled in the phase 3 trial for the drug Dupilumab...i hope i get it and not the placebo i really need it....

[jimmybob]

Regeneron upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Regeneron to Overweight with a $485 price target following recent survey results that indicates robust DME penetration for Elea. The analyst raised its Eylea 2015 estimate to 2.4B and 2016 to $2.7B and sees additional catalysts from further dupilumab data and Eylea ang2/PDGF combo data, and alirocumab approvals